nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2015 | Review

Production of ¹⁷⁷Lu for Targeted Radionuclide Therapy: Available Options

verfasst von: Ashutosh Dash, Maroor Raghavan Ambikalmajan Pillai, Furn F. Knapp Jr.

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background: This review provides a comprehensive summary of the production of ¹⁷⁷Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of ¹⁷⁷Lu having the required quality for preparation of a variety of ¹⁷⁷Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of ¹⁷⁷Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. Methods: While both “direct” and “indirect” reactor production routes offer the possibility for sustainable ¹⁷⁷Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. Results: This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. Conclusion: A broad understanding and discussion of the issues associated with ¹⁷⁷Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of ¹⁷⁷Lu-labeled radiopharmaceuticals, but also help future developments.

Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS. Radiometals for combined imaging and therapy. Chem Rev. 2013;113:858–83.PubMedCrossRef

Dash A, Knapp Jr FF, Pillai MRA. Targeted radionuclide therapy—an overview. Curr Radiopharm. 2013;6:152–80.PubMedCrossRef

Ramogida CF, Orvig C. Tumour targeting with radiometals for diagnosis and therapy. Chem Commun (Camb). 2013;49:4720–39.CrossRef

Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nucl Med. 1991;32:174–85.PubMed

Ercan MT, Caglar M. Therapeutic radiopharmaceuticals. Curr Pharm Des. 2000;6:1085–121.PubMedCrossRef

Guo H, Miao Y. Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorg Med Chem Lett. 2013;23:2319–23.PubMedCentralPubMedCrossRef

Yousefnia H, Jalilian AR, Zolghadri S, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M. Preparation and quality control of ¹⁷⁷Lu-[tris(1,10-phenanthroline) lutetium(III)] complex for therapy. Nucl Med Rev Cent Eas Eur. 2010;13:49–54.

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Practical aspects of peptide receptor radionuclide therapy with [¹⁷⁷Lu][DOTA0, Tyr3]octreotate. Q J Nucl Med Mol Imaging. 2006;50:265–71.PubMed

Knapp Jr FF, Mirzadeh S, Beets AL, Du M. Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for applications in nuclear medicine, oncology and interventional cardiology. J Radioanal Nucl Chem. 2005;263:503–9.CrossRef

10.

Firestone R. Table of Isotopes. 8th ed. New York: Wiley; 1996.

11.

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:103–12.PubMedCentralCrossRef

12.

Swärd C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, et al. Comparison of [¹⁷⁷Lu-DOTA0,Tyr³]-octreotate and [¹⁷⁷Lu-DOTA0,Tyr³]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm. 2008;23:114–20.PubMedCrossRef

13.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

14.

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.PubMedCrossRef

15.

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [¹⁷⁷Lu-DOTAOTyr³]octreotate: comparison with [¹¹¹In-DTPA^o]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–25.PubMedCrossRef

16.

Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33:1346–51.PubMedCrossRef

17.

Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with ¹⁷⁷Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with ⁹⁰Y-DOTATOC. J Nucl Med. 2005;46:1310–6.PubMed

18.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.PubMedCrossRef

19.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62.

20.

Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (¹⁷⁷)Lu- and (⁹⁰)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent Results Cancer Res. 2013;194:487–96.PubMed

21.

Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, et al. ¹⁷⁷Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.

22.

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with ¹⁷⁷Lu DOTA-TATE and ¹⁷⁷Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406–16.PubMedCrossRef

23.

Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [¹⁷⁷Lu-DOTA0, Tyr3]octreotate. J Nucl Med. 2011;52:1361–8.

24.

van Vliet EI, Hermans JJ, de Ridder MA, Teunissen JJ, Kam BL, de Krijger RR, et al. Tumor response assessment to treatment with [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. J Nucl Med. 2012;53:1359–66.PubMedCrossRef

25.

van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (¹⁷⁷)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51:383–9.PubMedCrossRef

26.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, et al. Anti-tumor effect and increased survival after treatment with [¹⁷⁷Lu-DOTA0, Tyr3]octreotate in a rat liver micrometastases model. Int J Cancer. 2003;104:376–9.

27.

Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, et al. ¹⁷⁷Lu-EDTMP : a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23:202–13.PubMedCrossRef

28.

Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Comparative studies of ¹⁷⁷Lu-EDTMP and ¹⁷⁷Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot. 2008;66:1196–205.PubMedCrossRef

29.

Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, et al. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of ¹⁷⁷Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol. 2010;37:215–26.PubMedCrossRef

30.

Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, et al. Efficacy and safety of ¹⁷⁷Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a Phase II study. Clin Nucl Med. 2013;38:88–92.PubMedCrossRef

31.

Abbasi IA. Preliminary studies on (¹⁷⁷)Lu-labeled sodium pyrophosphate (¹⁷⁷Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl Med Biol. 2012;39:763–9.PubMedCrossRef

32.

Abbasi IA. Studies on ¹⁷⁷Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl Med Biol. 2011;38:417–25.PubMedCrossRef

33.

Liu X, Li H, Xiang X, Luo Z, Wang Y, Kuai D, et al. Timing and optimized acquisition parameters for the whole-body imaging of ¹⁷⁷Lu-EDTMP toward performing bone pain palliation treatment. Nucl Med Commun. 2012;33:90–6.PubMedCrossRef

34.

Bard DR, Knight CG, Page-Thomas DP. Effect of the intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Clin Exp Rheumatol. 1985;3:237–42.PubMed

35.

Abbasi I, Ishfaq M, Sohaib M. Preparation and pre-clinical study of 177Lu-labelled hydroxyapatite for application in radiation synovectomy of small joints. Q J Nucl Med Mol Imaging. 2011;55:458–68.PubMed

36.

Chakraborty S, Das T, Banerjee S, Sarma HD, Venkatesh M. Preparation and preliminary biological evaluation of ¹⁷⁷Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun. 2006;27:661–8.PubMedCrossRef

37.

Teyssler P, Kolostova K, Bobek V. Radionuclide synovectomy in haemophilic joints. Nucl Med Commun. 2013;34:291–7.PubMedCrossRef

38.

Chakraborty S, Vimalnath KV, Rajeswari A, Shinto A, Sarma HD, Kamaleshwaran K, et al. Preparation, evaluation, and first clinical use of (¹⁷⁷) Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy. J Labelled Comp Radiopharm. 2014;57:453–62.PubMedCrossRef

39.

Chakraborty S, Vimalnath KV, Rajeswari A, Sarma HD, Shinto A, Radhakrishnan ER, et al. Radiolanthanide-labeled HA particles in the treatment of rheumatoid arthritis: ready-to-use cold kits for rapid formulation in hospital radiopharmacy. J Radioanal Nucl Chem. 2014;302:875–81.CrossRef

40.

Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37:1491–6.PubMed

41.

Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003;30:667–76.PubMedCrossRef

42.

Rasaneh S, Rajabi H, Babaei MH, Daha FJ, Salouti M. Radiolabeling of trastuzumab with ¹⁷⁷Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol. 2009;36:363–9.PubMedCrossRef

43.

Vera DR, Eigner S, Henke KE, Lebeda O, Melichar F, Beran M. Preparation and preclinical evaluation of ¹⁷⁷Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol. 2012;39:3–13.PubMedCrossRef

44.

Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke HR, Mueller-Brand J, et al. Radioimmunotherapy with ¹⁷⁷Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med. 2013;54:1045–52.PubMedCrossRef

45.

Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, et al. ¹⁷⁷Lu-Labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Mol Pharm. 2014;11:800–7.PubMedCrossRef

46.

Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, et al. Therapeutic efficacy of ¹⁷⁷Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92–104.PubMedCentralPubMedCrossRef

47.

Mughabghab SF. Atlas of Neutron Resonances, Resonance Parameters and Thermal Cross Sections, Z ¼ 1–100. Amsterdam: Elsevier; 2006.

48.

Nir-El Y. Production of ¹⁷⁷Lu by neutron activation of ¹⁷⁶Lu. J Radional Nucl Chem. 2004;3:563–7.CrossRef

49.

Dvorakova Z, Henkelmann R, Lin X, Turler A, Gerstenberg H. Production of ¹⁷⁷Lu at the new research reactor FRM-II: irradiation yield of ¹⁷⁶Lu(n, γ)¹⁷⁷Lu. Appl Radiat Isot. 2008;66:147–51.PubMedCrossRef

50.

Zhernosekov KP, Perego RC, Dvorakova Z, Henkelmann R, Türler A. Target burn-up corrected specific activity of ¹⁷⁷Lu produced via 176Lu(n, gamma) ¹⁷⁷Lu nuclear reactions. Appl Radiat Isot. 2008;66:1218–20.

51.

Holden NE. Temperature dependence of the Westcott g-factor for neutron reactions in activation analysis. Pure Appl Chem. 1999;71:2309–15.CrossRef

52.

De Corte F, Simonits A. Recommended nuclear data for use in the k0 standardization of neutron activation analysis. Atomic Data Nucl Data Tables. 2003;85:47–67.CrossRef

53.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–20.PubMedCrossRef

54.

Chakraborty S, Vimalnath KV, Lohar SP, Shetty P, Dash A. On the practical aspects of large-scale production of ¹⁷⁷Lu for peptide receptor radionuclide therapy using direct neutron activation of ¹⁷⁶Lu in a medium flux research reactor: The Indian experience. J Radioanal Nucl Chem. 2014;302:233–43.CrossRef

55.

Vimalnath KV, Shetty P, Lohar SP, Adya SVC, Thulasidas SK, Chakraborty S, et al. Aspects of yield and specific activity of (n, γ) produced ¹⁷⁷Lu used in targeted radionuclide therapy. J Radioanal Nucl Chem. 2014;302:809–12.

56.

Knapp Jr FF, Ambrose KR, Beets AL, Luo H, McPherson DW, Mirzadeh S. Nuclear medicine program progress report for quarter ending September 30, 1995. ORNL/TM-13107.

57.

Mirzadeh S, Du M, Beets AL, Knapp Jr FF. Method for preparing high specific activity ¹⁷⁷Lu. United States Patent. 2004;6716353:6.

58.

Henkelmann R, Hey A, Buck O, Zhernosekov K Nikula, T. Radiation Protection Aspects Related to Lutetium-177 Use in Hospitals, Abstracts of Intl. Workshop “Physics for Health in Europe” (CERN Geneva Switzerland, 2-4 February 2010), Book of Abstracts, 23 available at https://indico.cern.ch/event/70767/material/32/0.pdf .

59.

Hammond CR. The Elements, in Handbook of Chemistry and Physics 81st edition. CRC Press, Boca Raton, FL, & London, UK. 2000.

60.

Stary J. Separation of transplutonium elements. Talanta. 1966;13:421–37.PubMedCrossRef

61.

Denzler FO, Lebedev NA, Novgorodov AF, Roesch F, Qaim SM. Production and radiochemical separation of ¹⁴⁷Gd. Appl Radiat Isot. 1997;48:319–26.CrossRef

62.

Marhol M. Ion Exchangers in Analytical Chemistry: Their Properties and Use in Inorganic Chemistry. Praha, Prague, Czech Republic: Academia; 1982.

63.

Balasubramanian PS. Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target. J Radioanal Nucl Chem. 1994;185:305–10.CrossRef

64.

Hashimoto K, Matsuoka H, Uchida S. Production of no-carrier-added ¹⁷⁷Lu via the ¹⁷⁶Yb(n, γ)¹⁷⁷Yb → ¹⁷⁷Lu process. J Radioanal Nucl Chem. 2003;255:575–9.CrossRef

65.

Lahiri S, Nayak D, Nandy M, Das NR. Separation of carrier free lutetium produced in proton activated ytterbium with HDEHP. Appl Radiat Isot. 1998;49:911–3.CrossRef

66.

Kumrić K, Trtić-Petrović T, Koumarianou E, Archimandritis S, Čomor JJ. Supported liquid membrane extraction of ¹⁷⁷Lu(III) with DEHPA and its application for purification of ¹⁷⁷Lu-DOTA-lanreotide. Sep Pur Tech. 2006;51:310–31.CrossRef

67.

68.

Horwitz EP, Mc Alister DR, Bond AH, Barrans RE, Williamson JM. A process for the separation of ¹⁷⁷Lu from neutron irradiated ¹⁷⁶Yb targets. Appl Radiat Isot. 2005;63:23–36.PubMedCrossRef

69.

Le VS, Morcos N, Zaw M, Pellegrini P, Greguric I. Alternative chromatographic processes for no-carrier added ¹⁷⁷Lu radioisotope separation. Part I. Multi-column chromatographic process for clinically applicable. J Radioanal Nucl Chem. 2008;277:663–73.CrossRef

70.

Le VS, Morcos N, Zaw M, Pellegrini P, Greguric I, Nevissi A. Alternative chromatographic processes for no-carrier added ¹⁷⁷Lu radioisotope separation. Part II. The conventional column chromatographic separation combined with HPLC for high purity. J Radioanal Nucl Chem. 2008;277:675–83.CrossRef

71.

Dash A, Chakravarty R. Electrochemical separation: promises, opportunities, and challenges to develop next-generation radionuclide generators to meet clinical demands. Ind Eng Chem Res. 2014;53:3766–77.CrossRef

72.

Chakravarty R, Dash A, Pillai MRA. Electrochemical separation is an attractive strategy for development of radionuclide generators for medical applications. Curr Radiopharm. 2012;5:271–87.PubMedCrossRef

73.

Marsh JK. Rare earth metal amalgams, Part 1. J Chem Soc. 1942;1:398–401.CrossRef

74.

Marsh JK. Rare earth metal amalgams, Part 2. J Chem Soc. 1942;1:523–6.CrossRef

75.

Marsh JK. Rare earth metal amalgams, Part 3. J Chem Soc. 1943;2:8–10.CrossRef

76.

Marsh JK. Rare earth metal amalgams, Part 4. J Chem Soc. 1943;2:531–5.CrossRef

77.

McCoy HN. Europium and ytterbium amalgams. J Am Chem Soc. 1941;63:1622–4.CrossRef

78.

Onstott EI. The separation of europium from samarium by electrolysis. J Am Chem Soc. 1955;77:2129–32.CrossRef

79.

Onstott EI. Separation of the Lanthanons at Amalgam Cathodes. II. The separation of samarium from gadolinium and purification of europium at a lithium amalgam cathode. J Am Chem Soc. 1956;78:2070–6.CrossRef

80.

Lebedev NA, Novgorodov AF, Misiak R, Brockmann J, Roesch F. Radiochemical separation of no-carrier-added 177Lu as produced via the ¹⁷⁶Yb(n, γ)¹⁷⁷Yb → ¹⁷⁷Lu process. Appl Radiat Isot. 2000;53:421–5.

81.

Bilewicz A, Zuchowska K, Bartos B. Separation of Yb as YbSO₄ from ¹⁷⁶Yb target for production of ¹⁷⁷Lu via the ¹⁷⁶Yb(n, γ)¹⁷⁷Yb → ¹⁷⁷Lu process. J Radioanal Nucl Chem. 2009;280:167–9.CrossRef

82.

Chakravarty R, Das T, Dash A, Venkatesh M. An electro-amalgamation approach to isolate no-carrier-added ¹⁷⁷Lu from neutron irradiated ¹⁷⁷Yb for biomedical applications. Nucl Med Biol. 2010;37:811–20.PubMedCrossRef

83.

Hermanne A, Takacs S, Goldberg MB, Lavie E, Shubin YN, Kovalev S. Deuteron-induced reactions on Yb: Measured cross sections and rationale for production pathways of carrier-free, medically relevant radionuclides. Nucl Instr Meth B. 2006;247:223–31.CrossRef

84.

Manenti S, Groppi F, Gandini A, Gini L, Abbas K, Holzwarth U, et al. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity Lu-177 g in no carrier added form for metabolic radiotherapy. Appl Radiat Isot. 2011;69:37–45.PubMedCrossRef

85.

Tárkányi F, Ditrói F, Takács S, Hermanne A, Yamazaki H, Baba M, et al. Activation cross-sections of longer lived products of deuteron induced nuclear reactions on ytterbium up to 40 MeV. Nucl Instr Meth B. 2013;304:36–48.CrossRef

Titel: Production of 177Lu for Targeted Radionuclide Therapy: Available Options
verfasst von: Ashutosh Dash
Maroor Raghavan Ambikalmajan Pillai
Furn F. Knapp Jr.
Publikationsdatum: 01.06.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 2/2015
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-014-0315-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Production of ¹⁷⁷Lu for Targeted Radionuclide Therapy: Available Options

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Erratum to: Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Lymphadenopathy by Scrub Typhus Mimicking Metastasis on FDG PET/CT in a Patient with a History of Breast Cancer

Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer

Precision of SPECT/CT Allows the Diagnosis of a Hidden Brodie’s Abscess of the Talus in a Patient with Sickle Cell Disease

Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer